2022 Satellite Meeting
Drug Discovery for Ion Channels XXII

Friday, February 18, 8:30 AM - 5:15 PM
Esplanade, Room 153, Moscone Center

On-site registration WILL NOT be available.

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. The advent of higher throughput automated electrophysiology systems changed the face of ion channel drug discovery.

This year’s meeting will highlight presentations from drug discovery companies, companies that provide ion channel services to drug discovery companies and companies that provide products to ion channel drug discovery companies, as well as other speakers in the field of ion channel drug discovery, including several academic speakers.

BPS will be adhering to the city of San Francisco’s requirement of proof of vaccination for large events at indoor venues. Only individuals who are fully vaccinated with a FDA-authorized vaccine or a vaccine authorized for emergency use by the World Health Organization will have access to the Moscone Center. Everyone is required to be fully vaccinated whether he or she is a presenter, attendee, exhibitor, vendor, guest, or staff member. Masks will also be required. Additional details, including instructions for the verification process will be provided at a later date.


8:00 AM - 8:30 AM

Registration and Coffee
8:30 AM - 8:45 AM Niels Fertig, Nanion Technologies, Germany
Welcome and Opening Remarks

Session I Chair: Daniel Sauter, Sophion Bioscience, Denmark

8:45 AM - 9:30 AM

Keynote Speaker: Henry Colecraft, Columbia University, USA
Regulating Ion Channel Functional Expression and Gating with Engineered Nanobodies
9:30 AM - 10:00 AM Robert Kirby, Metrion Biosciences, United Kingdom
Development of a Current-Clamp Assay as a Physiologically Relevant Screen for Kv1.3
10:00 AM - 10:30 AM Fitzwilliam Seibertz, University of Göttingen, Germany
High Performance Characterization of Atrial Cardiomyocytes
10:30 AM - 11:00 AM Coffee Break

Session II Chair: Ali Yehia, Fluxion Biosciences, USA

11:00 AM - 11:30 AM Mohammad-Reza Ghovanloo, Yale University, USA
Inhibition of Sodium Conductance by Cannabigerol Contributes to a Reduction of Neuronal Dorsal Root Ganglion Excitability
11:30 AM - 12:00 PM Ciria Hernandez, University of Michigan, USA
High-throughput Functional Evaluation of Melanocortin Compounds in the MC4R-Kir7.1 Complex: Biased Signaling at the Melanocortin Receptor 4

12:00 PM - 12:30 PM 

Eric Wang, University of Florida, USA
Cell Lines to Facilitate Studies of GABA Receptor Subunit Combinations

12:30 PM - 1:30 PM

Lunch (Provided)

Session III Chair: Niels Fertig, Nanion Technologies, Germany

1:30 PM - 2:00 PM Arpad Mike, Eötvös Loránd University, Hungary
An Investigation of Sodium Channel Blocker Distribution Dynamics Using the Ionflux Mercury: Why Onset is Not Association, Offset is Not Dissociation, and Block is Not Really Block?
2:00 PM - 2:30 PM David Dalrymple, SB Drug Discovery, United Kingdom
Development of a Screening Cascade for Identification of TMEM175 Modulators
2:30 PM – 3:00 PM Coffee Break

Session IV Chair: Robert Kirby, Metrion Biosciences, United Kingdom

3:00 PM - 3:25 PM

Kris Kahlig, Praxis Precision Medicines, USA
Using Dynamic Action Potential Clamp Modeling of Nav1.2 Variants to Support the Prediction of Clinical Phenotype in DEE

3:25 PM - 3:50 PM Andrea Fleig, University of Hawaii, USA
Natural Products as Modulators of Calcium Signaling in Inflammation
3:50 PM - 4:15 PM Andrew Jenkins, Emory University, USA
Using Electrophysiology as a Translational Tool in the Ohmic Era
4:15 PM - 4:40 PM Paul Slesinger, Icahn School of Medicine at Mount Sinai, USA
Targeting GIRK Potassium Channels for Treating Alcoholism
4:40 PM - 4:45 PM Daniel Sauter, Sophion Bioscience, Denmark
Closing Remarks

Sponsored by: